Преждевременная недостаточность яичников: последствия для здоровья и стратегии заместительной гормональной терапии

   Цель обзора: анализ современных взглядов на патогенез осложнений и отдаленных последствий дефицита половых гормонов среди пациенток с преждевременной недостаточностью яичников (ПНЯ), а также возможностей и стратегий заместительной гормональной терапии (ЗГТ) для их лечения и профилактики.

   Основные положения. Последствиями дефицита половых гормонов при ПНЯ являются не только краткосрочные клинические проявления, схожие с климактерическими, но и отдаленные негативные исходы для общего здоровья и жизни. ЗГТ обладает терапевтическим и профилактическим потенциалом в отношении всех клинических аспектов ПНЯ. Однако выработанные в настоящее время стандартные терапевтические стратегии не всегда позволяют полностью купировать симптомы ПНЯ и обеспечить надежную профилактику осложнений.

   Заключение. Выбор адекватных доз и состава ЗГТ, наряду с междисциплинарным подходом в лечении ПНЯ, позволят нивелировать связанные с ней риски и обеспечить высокое качество жизни пациенток.

1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027

2. Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547

3. Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1

4. van Kasteren Y.M., Schoemaker J. Premature ovarian failure : a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483

5. Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1

6. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046

7. Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110

8. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041

9. Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017

10. Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330

11. Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292

12. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality : a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415

13. Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374

14. Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261

15. Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0

16. Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516

17. Ostberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.x

18. El Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause : A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003

19. Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512

20. Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82

21. Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358

22. Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010

23. Bachelot A., Nicolas C., Gricourt S. et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One. 2016;11:e0164638. DOI: 10.1371/journal.pone.0164638

24. Xu X., Jones M., Mishra G.D. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum. Reprod. 2020;35:203–211. DOI: 10.1093/humrep/dez259

25. Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145

26. Shah S., Nguyen H.H., Vincent A.J. Care of the adult woman with Turner syndrome. Climacteric. 2018;21(5):428–436. DOI: 10.1080/13697137.2018.1476969

27. Manolaga S.C. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 2013;9(12):699–712. DOI: 10.1038/nrendo.2013.179

28. Burgos N., Cintron D., Latortue-Albino P. et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. Endocrine. 2017;58(3):413–425. DOI: 10.1007/s12020-017-1435-x

29. Cintron D., Rodriguez-Gutierrez R., Serrano V. et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome : a systematic review and meta-analysis. Endocrine. 2017;55(2):366–375. DOI: 10.1007/s12020-016-1046-y

30. Cui X., Cui Y., Shi L. et al. A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis. Res. 2018;7(4):223–228. DOI: 10.5582/irdr.2017.01056

31. Benetti-Pinto C.L., Ferreira V.B., Yela D.A. Long-term follow-up of bone density in women with primary ovarian insufficiency. Menopause. 2015;22(9):946–949. DOI: 10.1097/GME.0000000000000445

32. Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145

33. Zuckerman-Levin N., Frolova-Bishara T., Militianu D. et al. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 2009;94(12): 4820–4827. DOI: 10.1210/jc.2009-0514

34. Hewlett M., Mahalingaiah S. Update on primary ovarian insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 2015;22(6):483–489. DOI: 10.1097/MED.0000000000000206

35. Nappi R.E., Cucinella L., Martini E. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22:289–295. DOI: 10.1080/13697137.2019.1575356

36. van der Stege J.G., Groen H., van Zadelhoff S.J. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23–31. DOI: 10.1097/gme.0b013e3180f6108c

37. De Almeida D.M., Benetti-Pinto C.L., Makuch M.Y. Sexual function of women with premature ovarian failure. Menopause. 2011;18(3):262–266. DOI: 10.1097/gme.0b013e3181f4318d

38. Schmidt P.J., Luff J.A., Haq N.A. et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011;96(2):E278–E287. DOI: 10.1210/jc.2010-0613

39. Liao K.L., Wood N., Conway G.S. Premature menopause and psychological well-being. J. Psychosom. Obstet. Gynaecol. 2000;21(3):167–174. DOI: 10.3109/01674820009075624

40. Mann E., Singer D., Pitkin J. et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 2012;15(5):481–489. DOI: 10.3109/13697137.2011.647841

41. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023;(5):50–58. DOI: 10.18565/aig.2023.16

42. Calik-Ksepka A., Grymowicz M., Rudnicka E. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz Menopauzalny. 2018;17(3):131–134. DOI: 10.5114/pm.2018.78558

43. Faubion S.S., Sood R., Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin. Proc. 2017;92(12):1842–1849. DOI: 10.1016/j.mayocp.2017.08.019

44. Bonetti-Pinto C.L., Giraldo P.C., Pacello P.C.C. et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women. Arch. Gynecol. Obstet. 2015;292:159–164. DOI: 10.1007/s00404-015-3616-2

45. Rocca W.A., Bower J.H., Maraganore D.M. et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. DOI: 10.1212/01.wnl.0000276984.19542.e6

46. Bove R., Secor E., Chibnik L.B. et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–229. DOI: 10.1212/WNL.0000000000000033